Anti-proliferative activity was observed in human leukemia cell lines as well as in CD34+ cells derived from newly diagnosed CML patients or IM-resistant individuals in chronic phase and blast crisis, including those harboring a T315I mutation [27], [28]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.